LMT Lombard Med.Tec

TIDMLMT

RNS Number : 1969B

Lombard Medical Technologies PLC

28 February 2014

Lombard Medical Technologies PLC

("Lombard Medical", or "the Company")

Directorate Change

London, UK, February 28, 2014 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on Endovascular Aortic Repair ("EVAR") of abdominal aortic aneurysms ("AAAs"), announced today that Professor Martin Rothman has left the Board after serving as a Non-Executive Director for over a decade.

Raymond W. Cohen, Non-Executive Chairman of Lombard Medical, commented:

"On behalf of all stakeholders, I would like to thank Prof. Rothman for his commitment and long service to Lombard Medical. He leaves with our very best wishes for his future endeavors."

-Ends-

For further information:

 
 Lombard Medical Technologies PLC       Tel: +44 (0)1235 750 800 
  Simon Hubbert, Chief Executive 
  Officer 
  Ian Ardill, Chief Financial Officer 
 
 Canaccord Genuity Limited (Nomad)      Tel: +44 (0)20 7523 8000 
  Lucy Tilley / Tim Redfern / Henry 
  Fitzgerald O'Connor / Dr Julian 
  Feneley 
 
 FTI Consulting (UK)                    Tel: +44 (0)20 7831 3113 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell 
 

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year over 500,000 new cases are diagnosed. In the US, aortic aneurysm disease is among the leading causes of death and it is estimated that 1.7 million people over the age of 55 have an abdominal aortic aneurysm.

About Lombard Medical

Lombard Medical Technologies PLC is a focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm repair market. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy often present in advanced AAA disease. Aorfix is the only stent graft with US FDA approval for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. The Company is headquartered in Oxfordshire, England with US operations in Irvine, CA.

Further background on the Company can be found at www.lombardmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAPGUAWPUPCURR

Lombard Medical Technologies (LSE:LMT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Lombard Medical Technologies (LSE:LMT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024